N-tosyl-asparagine | 62743-18-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-tosyl-asparagine
• 英文别名: N²-(toluene-sulfonyl-(4))-DL-asparagine；N²-(toluene-4-sulfonyl)-DL-asparagine；N²-(Toluol-4-sulfonyl)-DL-asparagin；N²-(Toluol-sulfonyl-(4))-DL-asparagin；N²-(Toluol-4-sulfonyl)-asparagin；N^α-p-Toluolsulfonyl-asparagin；2-(Toluene-4-sulfonylamino)-succinamic acid；4-amino-2-[(4-methylphenyl)sulfonylamino]-4-oxobutanoic acid
• CAS: 62743-18-4
• 化学式: C₁₁H₁₄N₂O₅S
• 分子量: 286.309
• InChiKey: VZCCSZRICJFBSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  N-tosyl-asparagine 在 tetraphosphorus decasulfide 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 生成 benzyl 2-{[(4-methylphenyl)sulfonyl]amino}-3-(4-methyl-1,3-thiazol-2-yl)propanoate
  参考文献：
  名称：

  Synthesis of thiazole-containing amino acids based on asparagine

  摘要：

  通过将天冬酰胺依次转化为硫代类似物，然后与 α-溴酮反应的汉茨赫反应，获得了许多早期未知的含噻唑氨基酸。

  DOI：

  10.1007/s11172-014-0579-6
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氨 、 水 作用下， 生成 N-tosyl-asparagine
  参考文献：
  名称：

  Bovarnick, Journal of Biological Chemistry, 1943, vol. 148, p. 151

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE)<br/>[FR] COMPOSES HETEROCYCLIQUES BLOQUANT LES EFFETS DES PRODUITS TERMINAUX AVANCES DE GLYCATION
  申请人：REDDYS LAB LTD DR

  公开号：WO2005040163A1

  公开（公告）日：2005-05-06

  The present invention relates to novel compounds of Formula (Ia) or (Ib), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. Formula (Ia), or Formula (Ib) in the above formulae L represents Formula (I), Formula (II) or -(CH2)1- Q represents Formula (III), or Formula (IV). The present invention also relates to a process for the preparation of the above said novel compounds, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory responses in tissues, including endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. The present invention also relates to compounds that act as modulators of Perlecan activity and expression. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPG) such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as stenosis, restenosis, neointimal hyperplasia, and atherosclerosis. The compounds of Formula (I) are also useful for the treatment and/or prevention of cancer. The types of cancers include melanoma, prostate, leukemia, lymphoma, non-small lung cancers, cancer of the central nervous system, breast, colon, ovarian or renal cancer.

  本发明涉及公式（Ia）或（Ib）的新化合物，它们的药学上可接受的盐以及含有它们的药学上可接受的组合物。在上述公式中，公式（Ia）或公式（Ib）中的L代表公式（I）、公式（II）或-(CH2)1-，Q代表公式（III）或公式（IV）。本发明还涉及制备上述新化合物、其药学上可接受的盐和含有它们的药物组合物的方法。本发明还涉及包括治疗由炎症反应引起的病理生理条件的化合物的方法和组合物。具体而言，本发明涉及抑制或阻断组织中糖化蛋白诱导的与信号相关的炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。本发明还涉及作为Perlecan活性和表达调节剂的化合物。具体而言，本发明涉及通过调节肝素硫酸蛋白聚糖（HSPG）如Perlecan来抑制平滑肌细胞增殖的化合物。本发明进一步涉及利用化合物治疗由平滑肌增殖特征的血管闭塞性疾病，如狭窄、再狭窄、新内膜增生和动脉粥样硬化。公式（I）的化合物也可用于治疗和/或预防癌症。癌症类型包括黑色素瘤、前列腺癌、白血病、淋巴瘤、非小细胞肺癌、中枢神经系统癌症、乳腺癌、结肠癌、卵巢癌或肾癌。
• Heterocyclic compounds and methods of making and using thereof
  申请人：Rao Koteswar Yeleswarapu

  公开号：US20050119269A1

  公开（公告）日：2005-06-02

  Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided.

  提供化学式(I)的化合物，以及包含这些化合物的方法和/或组合物，这些化合物对调节由AGE和糖基化蛋白堆积引起的炎症反应有效。还提供了有效调节平滑肌细胞增殖及其相关疾病或病况的方法和/或组合物。
• Coordination behaviour of Ar-SO2-N-amino acids toward the Mn(II) ion. Crystal and molecular structure of [Mn(tsgln)2] and [Mn(tS-DL-α-ala)2(H2O)]·2.78H2O·0.92CH3OH
  作者：Sergio Brückner、Ledi Menabue、Monica Saladini、Marilena Tolazzi

  DOI：10.1016/s0020-1693(00)87542-8

  日期：1993.12

  A series of complexes of Ar-SO2-N-amino acids (Ar-SO2-= 4-toluensulfonyl- (hereafter abbreviated as tosyl) (ts), benzenesulfonyl (bs); amino acid=glycine (gly), DL-alpha- and beta-alanine (alpha- and beta-ala), asparagine (asn) and glutamine (gln)) with Mn(II) was synthesized and characterized by means of spectroscopic and thermal analyses. For two of them [Mn(ts-alpha-ala)2(H2O)].2.78H2O.0.92CH3OH (1) and [Mn(tsgln)2] (II) the crystal and molecular structure was also determined. I crystallizes in the orthorhombic Pbcn space group, with cell dimensions: a = 31.212(3), b = 11.248(2), c = 9.051(2) angstrom, Z = 4. II crystallizes in the monoclinic C2 space group, with cell dimensions: a = 17.490(3), b = 5.259(2), c = 17.432(2) angstrom, beta = 120.70(4)-degrees, Z = 2. In both compounds the Mn(II) atom is octahedrally coordinated by six oxygen atoms. In I the amino acid monoanion bridges two Mn atoms through the carboxyl group giving rise to a 1D polymer, the coordination to Mn is completed by two water molecules in a special position. In II each amino acid monoanion bridges two Mn atoms through the carboxyl group and binds a third Mn atom through the carbonyl oxygen of the terminal amide group, giving rise to a 2D polymer.
• Influence of 4-toluenesulphonyl group on the coordination properties of dl-asparagine and l-glutamine
  作者：Ledi Menabue、Monica Saladini、Paola Morini

  DOI：10.1016/s0277-5387(00)83841-3

  日期：1989.1
• HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF
  申请人：Reddy US Therapeutics, Inc.

  公开号：EP1678157A2

  公开（公告）日：2006-07-12